Organization
Neonc Technologies
4 clinical trials
Clinical trial
An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 MutationStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.Status: Recruiting, Estimated PCD: 2026-02-28
Clinical trial
An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade MeningiomaStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
An Open Label, Phase 1b Safety, Dose-finding, Brain Tumor Delivery, and Pharmacokinetics Study of Intranasal NEO100 in Patients With Pediatric-type Select Brain TumorsStatus: Not yet recruiting, Estimated PCD: 2024-10-31